Indefinite Delivery Contract 36C26026D0022
- Not listed
- RLS (USA) Inc. was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs Veterans Integrated Service Network 22 to supply radiopharmaceuticals for nuclear medicine diagnostic imaging services. The contract has a ceiling value of $320,306.45 with a performance period from December 12, 2025, through December 11, 2026, and utilizes firm fixed-price pricing with no set-aside designation. The underlying solicitation (36C26226Q0072), posted by the VA San Diego...
- RLS (USA) Inc., a small business foreign-owned radiopharmacy company, was awarded a single-award Indefinite Delivery Contract by Veterans Integrated Service Network 5 (VISN 5), a component of the Department of Veterans Affairs, with a ceiling value of $2,162,919.87 and a performance period extending through March 31, 2030. The contract, awarded April 1, 2025, procures radiopharmaceuticals—specialized pharmaceutical products essential for nuclear medicine diagnostic imaging services at VA medical...
- RLS USA Inc. was awarded an indefinite delivery contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 17 to provide radiopharmaceutical products. The potential value of the contract is $1,162,500. No set-aside designation was applied. Under the contract, RLS USA Inc. received two delivery orders to date for radiopharmaceutical supplies. The first delivery order, valued at $244,564.67, was awarded on August 2, 2022 for a performance...
- The Department of Veterans Affairs (VA), Veterans Integrated Service Network 21 has awarded an Indefinite Delivery Contract (IDC) worth up to $1,200,000 to RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company, to provide radiopharmaceuticals and related supplies to VA medical centers and military treatment facilities. The initial task order under this IDC is valued at $179,605.38 and covers the delivery of radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18,...
- This federal contract IDV award is a single-award indefinite delivery contract between the U.S. Department of Veterans Affairs (VA) and the prime contractor RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract has a total ceiling value of $249,500 and a performance period ending on March 31, 2025. Under this IDV, RLS (USA) Inc. will supply a variety of non-PET radiopharmaceuticals to support nuclear medicine diagnostic services at VA medical centers and military...
- This indefinite delivery contract was awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 17 to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract is for the provision of critical radiopharmaceuticals, including gallium-67, fluorodeoxyglucose F-18, thallium-201, technetium-99m, and Gallium-68 Dotatate, which are used in nuclear medicine imaging procedures and diagnostic services provided to veterans and military personnel....
- This single-award Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) to RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company, to provide radiopharmaceuticals and related supplies to the VA Northern California Health Care System (VANCHCS). The contract has a ceiling value of $2,500,000 and a performance period through March 31, 2030. Under this IDC, RLS (USA) Inc. will deliver radiopharmaceuticals such as gallium-67, fluorodeoxyglucose F-18,...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded an indefinite delivery contract to RLS USA Inc. to provide non-PET radiopharmaceuticals in support of nuclear medicine services. The contract established a potential value of $733,420.11 over its period of performance from October 2021 through September 2024. Delivery orders issued against this contract included awards of $251,729.90, $244,402.04, and $650,585.28 to RLS USA Inc. for...
- This indefinite delivery contract (IDC) was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2), a civilian agency, to the prime contractor RLS (USA) Inc., a foreign-owned for-profit radiopharmacy company. The contract, valued at $538,493.10, is for the delivery of the radiopharmaceutical product NETSPOT GA-68 to support nuclear medicine imaging procedures at VA medical facilities. RLS (USA) Inc. holds several federal IDV contracts with the VA...
- This federal Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) to RLS (USA) Inc., a foreign-owned, for-profit radiopharmacy company. The contract is for the delivery of non-positron emission tomography (non-PET) radiopharmaceuticals to support nuclear medicine diagnostic services at VA medical centers. The contract has a performance period from April 1, 2025, to March 31, 2026, with a ceiling value of $425,725.07. RLS (USA) Inc. is an experienced federal...
- 36C26026D0022Indefinite Delivery Contract
- 1Federal Contract Awards
RLS (USA) Inc. has been awarded a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract by the Department of Veterans Affairs Veterans Integrated Service Network 20 (VISN 20) to supply radiopharmaceuticals for nuclear medicine diagnostic and therapeutic applications. The contract, valued at $3.0 million with a performance period spanning January 1, 2026, through December 31, 2030, supports the VA's nuclear medicine imaging programs serving veteran patients throughout the VISN 20 service region. The procurement encompasses approximately 40 different radiopharmaceutical products, including Technetium-99m compounds, Iodine-123, Iodine-131, Gallium-67, Indium-111, Gallium-68 Dotatate (NETSPOT), fluorodeoxyglucose F-18, and thallium-201, with dose ranges specified from 5 millicuries to 30 millicuries for diagnostic studies and up to 150 millicuries for therapeutic applications. RLS (USA) Inc., operating 31 radiopharmacy facilities across 18 states, will perform the contract with primary delivery operations based in Lake Mary, Florida, ensuring time-sensitive delivery of precisely calibrated doses to VA medical facilities. The contract is structured without set-aside provisions and requires the contractor to maintain comprehensive quality control documentation and full compliance with all federal and state regulatory requirements. Under this IDIQ contract, delivery orders are issued on an as-needed basis to procure radiopharmaceutical products for specific quantities and delivery periods. A delivery order issued January 1, 2026, for performance through December 31, 2026, exemplifies contract execution, with a ceiling value of approximately $494 thousand under firm fixed-price terms. Contract requirements include precise dose calibration at requested dates and times, with replacement doses provided at no charge for weather delays or patient cancellations, ensuring continuity of care for diagnostic and therapeutic nuclear medicine procedures. RLS (USA) Inc.'s established distribution network and specialized capabilities in radiopharmaceutical supply position the company as a critical supplier to federal healthcare agencies, with this contract reflecting the VA's continued reliance on the contractor's logistics and regulatory compliance expertise to support veterans' nuclear medicine diagnostic services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 12/31/25 |
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
Delivery Order 36C26026D0022-36C26026N0143 | RLS (USA) Inc. | $494.0k | 1/1/26 | 12/31/26 | 12/31/25 |
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Radiopharmaceuticals for nuclear medicine patients | Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 | Special Notice 2/2 | 10/31/25, 11:14 AM | ||
Radiopharmaceuticals for nuclear medicine patients | 36C26026Q0055 | Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 | Solicitation 1/2 | 10/20/25, 4:30 PM |